{"title":"妇科恶性肿瘤抗肿瘤药物监管审批试验的合理研究终点","authors":"M. Markman","doi":"10.1177/1745505716655555","DOIUrl":null,"url":null,"abstract":"A discussion of rational endpoints in clinical trials seeking regulatory approval for new anti-neoplastic agents involving the three major gynecologic malignancies, cancers of the ovary, cervix, and endometrial, is particularly interesting as (in the opinion of this commentator) the conclusion will be different in the individual cancers.","PeriodicalId":20389,"journal":{"name":"Pregnancy and Women’s Health Care International Journal","volume":"240 1","pages":"396 - 399"},"PeriodicalIF":0.0000,"publicationDate":"2016-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies\",\"authors\":\"M. Markman\",\"doi\":\"10.1177/1745505716655555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A discussion of rational endpoints in clinical trials seeking regulatory approval for new anti-neoplastic agents involving the three major gynecologic malignancies, cancers of the ovary, cervix, and endometrial, is particularly interesting as (in the opinion of this commentator) the conclusion will be different in the individual cancers.\",\"PeriodicalId\":20389,\"journal\":{\"name\":\"Pregnancy and Women’s Health Care International Journal\",\"volume\":\"240 1\",\"pages\":\"396 - 399\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pregnancy and Women’s Health Care International Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/1745505716655555\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pregnancy and Women’s Health Care International Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1745505716655555","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies
A discussion of rational endpoints in clinical trials seeking regulatory approval for new anti-neoplastic agents involving the three major gynecologic malignancies, cancers of the ovary, cervix, and endometrial, is particularly interesting as (in the opinion of this commentator) the conclusion will be different in the individual cancers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
